OCA
Octagon Capital Advisors Portfolio holdings
AUM
$456M
This Quarter Return
+21.34%
1 Year Return
+48.55%
3 Year Return
+560.4%
5 Year Return
–
10 Year Return
–
AUM
$483M
AUM Growth
+$483M
(+82%)
Cap. Flow
+$204M
Cap. Flow
% of AUM
42.29%
Top 10 Holdings %
Top 10 Hldgs %
66.04%
Holding
36
New
8
Increased
7
Reduced
–
Closed
2
Top Buys
| 1 |
Apellis Pharmaceuticals
APLS
|
$44.7M |
| 2 |
IMAB
I-MAB
IMAB
|
$34.7M |
| 3 |
BridgeBio Pharma
BBIO
|
$23.2M |
| 4 |
Zai Lab
ZLAB
|
$19.4M |
| 5 |
Vera Therapeutics
VERA
|
$15M |
Top Sells
| 1 |
CCXI
ChemoCentryx, Inc.
CCXI
|
$7.69M |
| 2 |
Foghorn Therapeutics
FHTX
|
$911K |
Sector Composition
| 1 | Healthcare | 99.38% |
| 2 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Apellis Pharmaceuticals
APLS
$3.48B
| $79.4M | 16.44% | 1,256,265 +707,891 | +129% | +$44.7M |
|
|
IMAB
2
I-MAB
IMAB
$340M
| $79.2M | 16.4% | 943,156 +413,106 | +78% | +$34.7M |
|
3
Curis
CRIS
$20.9M
| $28.9M | 5.99% | 3,582,629 +1,454,229 | +68% | +$11.7M |
|
|
4
BridgeBio Pharma
BBIO
$9.89B
| $23.2M | 4.81% | +380,928 | New | +$23.2M |
|
5
Arcus Biosciences
RCUS
$1.13B
| $20.9M | 4.32% | 760,164 +360,164 | +90% | +$9.89M |
|
6
4D Molecular Therapeutics
FDMT
$288M
| $20M | 4.15% | 831,267 +452,979 | +120% | +$10.9M |
|
|
7
Zai Lab
ZLAB
$3.68B
| $19.4M | 4.01% | +109,335 | New | +$19.4M |
|
8
Celldex Therapeutics
CLDX
$1.47B
| $18.8M | 3.89% | 561,398 | – | – |
|
|
9
Vera Therapeutics
VERA
$1.38B
| $15M | 3.11% | +1,132,671 | New | +$15M |
|
|
XLRN
10
DELISTED
Acceleron Pharma Inc.
XLRN
| $14.1M | 2.92% | 112,363 | – | – |
|
11
Arvinas
ARVN
$568M
| $13.7M | 2.85% | 178,500 | – | – |
|
12
Dyne Therapeutics
DYN
$1.92B
| $12.3M | 2.54% | 583,649 | – | – |
|
13
Century Therapeutics
IPSC
$42.5M
| $11.8M | 2.45% | +403,523 | New | +$11.8M |
|
14
Gossamer Bio
GOSS
$562M
| $11.5M | 2.38% | 1,413,138 | – | – |
|
15
Avidity Biosciences
RNA
$5.99B
| $11M | 2.29% | 446,641 | – | – |
|
16
Stoke Therapeutics
STOK
$1.08B
| $9.99M | 2.07% | +296,822 | New | +$9.99M |
|
|
AMAM
17
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $8.82M | 1.83% | +450,000 | New | +$8.82M |
|
18
PMV Pharmaceuticals
PMVP
$74.2M
| $8.54M | 1.77% | 250,000 | – | – |
|
|
CNTB
19
Connect Biopharma
CNTB
$115M
| $7.29M | 1.51% | 373,492 | – | – |
|
20
Taysha Gene Therapies
TSHA
$797M
| $6.79M | 1.41% | 320,440 | – | – |
|
21
Cardiff Oncology
CRDF
$140M
| $6.54M | 1.35% | 982,753 +332,753 | +51% | +$2.21M |
|
|
IMA
22
ImageneBio, Inc. Common Stock
IMA
$150M
| $5.62M | 1.16% | 400,000 | – | – |
|
23
Monte Rosa Therapeutics
GLUE
$296M
| $5.4M | 1.12% | +238,045 | New | +$5.4M |
|
24
Design Therapeutics
DSGN
$315M
| $4.97M | 1.03% | 250,000 | – | – |
|
|
RXDX
25
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $4.91M | 1.02% | 200,000 | – | – |
|